Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia  by Florquin, Sandrine et al.
Kidney International, Vol. 59 (2001), pp. 2054–2061
Release of urokinase plasminogen activator receptor during
urosepsis and endotoxemia
SANDRINE FLORQUIN, JOSE´ G. VAN DEN BERG, DARIUSZ P. OLSZYNA, NIKE CLAESSEN,
STEVEN M. OPAL, JAN J. WEENING, and TOM VAN DER POLL
Departments of Pathology, Experimental Internal Medicine, Infectious Diseases Tropical Medicine and AIDS, Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and Brown University School of Medicine,
Memorial Hospital, Pawtucket, Rhode Island, USA.
Release of urokinase plasminogen activator receptor during course of urinary tract infection is determined by bacte-
urosepsis and endotoxemia. rial virulence factors and by host factors such as anatomi-
Background. The urokinase receptor (uPAR; CD87) is a cal abnormalities of the urinary tract and defense mecha-multifunctional molecule involved in fibrinolysis, in proteolysis,
nisms. Recently, attention has been paid to the role ofin renal tubular functions, and in migration and adhesion of
various inflammatory pathways such as the local and sys-inflammatory cells to the site of infection.
Methods. To gain insight into systemic and local release of temic production of inflammatory cytokines and chemo-
uPAR and into its regulation during urosepsis, which is one kines in the resistance to urinary tract infections [2–5]. A
of the leading causes of chronic renal failure, uPAR was mea- compensatory anti-inflammatory response generated atsured in urine and plasma of healthy human controls (N 5 20),
the systemic level takes also place during urosepsis andpatients with culture-proven urosepsis (N 5 30), and healthy
is characterized by the release of interleukin-10 (IL-10),human volunteers intravenously injected with endotoxin
(N 5 7). soluble tumor necrosis factor (TNF) receptors, and IL-1
Results. Patients had elevated uPAR levels in both plasma receptor antagonist [6].
and urine. Three hours after endotoxin challenge in volunteers, Although urokinase type plasminogen activator (uPA)there was also a significant increase of uPAR in plasma and
and its receptor (uPAR; CD87) were originally discov-in urine. The urine/plasma ratio for uPAR was highly elevated
ered in the urine as implied by the name, the role ofduring urosepsis and experimental endotoxemia, suggesting
local production in the kidney. Accordingly, damaged tubuli uPAR has not been studied during urinary tract infec-
strongly expressed uPAR during pyelonephritis. Moreover, tu- tions. uPAR is present at the cell surface of monocytes/
bular epithelial cells produced uPAR in vitro, and this secretion macrophages [7, 8], neutrophils [9], T cells [10], endothe-was strongly up-regulated after stimulation with interleukin-
lial cells [11], smooth muscle cells [12], and renal tubular1b or tumor necrosis factor-a.
epithelial cells [13]. Although uPAR is a glycosylphos-Conclusions. We found that uPAR is released systemically
and in the urinary tract during urosepsis and experimental phatidylinositol (GPI)-linked membrane protein and,
endotoxemia. This systemic and renal production of uPAR therefore, lacks the transmembrane and cytoplasmatic
during pyelonephritis may play a central role in eliminating
sequences to induce signal transduction, uPAR can formthe infection and protecting renal function.
complexes with CR3 (CD11b/CD18) on monocytes [14]
and granulocytes [15], thus resulting in signal transduc-
tion. The fibrinolytic system consists of a number ofUrinary tract infections, most frequently caused by
proteases and protease inhibitors that regulate the gener-Escherichia coli, are one of the most important bacterial
ation of plasmin, the active end product of this pathwayinfections in females and in childhood [1]. Acute pyelo-
that dissolves fibrin clots. The formation of cell-associ-nephritis is a frequent source of gram-negative sepsis
ated plasmin is triggered by the binding of uPA to itsand in 10 to 40% of cases leads to renal scarring. The
receptor. Besides its essential role in fibrinolysis, the
uPA/uPAR system also has an obligate function in che-
motaxis of neutrophils and macrophages [16, 17]. Indeed,Key words: CD87, nephrotoxicity, urinary tract infection, tubular epi-
thelial cells, cytokines, bacterial infection, anti-inflammatory response. the uPA/uPAR system plays a role in adhesion and mi-
gration of neutrophils to the site of inflammation byReceived for publication September 22, 2000
an effect on b2 integrins in vitro [9, 18–21]. Moreover,and in revised form January 5, 2001
Accepted for publication January 11, 2001 plasmin also induces proteolysis, which is a crucial step
for cell migration. These data indicate that the activationÓ 2001 by the International Society of Nephrology
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of the uPA/uPAR system can initiate the inflammatory at two, four, and eight hours thereafter. The samples
were centrifuged at 1500 3 g for 20 minutes. Superna-response, including chemotaxis and extravasation of in-
flammatory cells, necessary to clear the infection. In the tants were collected and stored at 2758C until assays
were performed. All patients fully recovered after treat-urinary tract, the uPA/uPAR system might fulfill addi-
tional and essential functions. The uPA-catalyzed pro- ment. Urine and heparinized blood were also collected
from 20 healthy individuals, all of whom had sterile urine.teolytic activity can play an important role in the preven-
tion of protein precipitation and subsequent tubular
Experimental endotoxemiaobstruction and preserve tubular function and integrity
under physiological and pathological conditions [22]. Al- In addition to the patients with urosepsis, seven
healthy subjects (mean age 6 SEM, 24 6 1 years) werethough the pathophysiological role of the uPA/uPAR
system in renal function remains to be studied, an in- studied after intravenous administration of endotoxin
[lipopolysaccharide (LPS)]. The subjects did not smoke,creasing number of studies correlate abnormalities in the
fibrinolytic system with both acute and chronic renal use any medication, or have a febrile illness in the month
preceding the study. They were admitted to the clinicaldiseases [23–26].
The present study sequentially measured plasma and research unit at the Academic Medical Center after their
medical history, physical examination, hematologicalurine concentrations of uPAR in patients with urosepsis
during the first eight hours after the initiation of antibi- and biochemical tests, chest x-ray, and echocardiogram
had proved normal. Endotoxin (lipopolysaccharide, LPSotic treatment and in healthy volunteers intravenously
injected with E. coli endotoxin. We also analyzed the standard lot G from E. coli obtained from the United
Stated Pharmacopeia Convention Inc., Rockville, MD,expression of uPAR by immunohistochemistry on renal
tissue of patients with pyelonephritis and its secretion USA) was given over one minute in an antecubital vein
at a dose of 4 ng/kg body weight. Blood was collected byin vitro by tubular epithelial cells.
venapunctures directly before LPS administration (t 5 0)
and at t 5 0.5, 1, 2, 3, 4, 5, 8, and 12 hours. Plasma was
METHODS
obtained by centrifuging at 1500 3 g for 20 minutes. The
Patients with urosepsis and controls urine was collected before LPS administration (t 5 0)
and at t 5 3 and 6 hours.Thirty patients (mean age 6 SEM, 42 6 3 years) with
culture proven gram-negative urosepsis were studied. The study was approved by the institutional scientific
and ethics committees. Written informed consent wasThe present study in patients with urosepsis was per-
formed simultaneously with an investigation determining obtained from all patients and healthy subjects.
the production of chemokines, the results of which have
Human kidney biopsiesbeen published previously [27]. Patients older than 18
years of age, suspected of having gram-negative uro- Human kidney samples were obtained either by percu-
taneous renal biopsies from patients with tubulointersti-sepsis and in whom antibiotic treatment was indicated,
were eligible when they met the following criteria: acute tial nephritis secondary to chronic pyelonephritis (N 5
2) or from autopsy of patients with chronic pyelonephri-symptoms of urinary tract infection, pyuria (leukocytes
.10/hpf with epithelial cells ,5/hpf), urine gram stain tis (N 5 4). As control, we used a normal part of kidneys
removed by nephrectomy for renal cell carcinoma (N 5with gram-negative bacteria, and metabolic or hemato-
logic signs of systemic infection, including two of the 5). All samples were frozen in liquid nitrogen without
prefixation for immunohistochemical study.following three indicators: tachycardia (.90 beats/min),
leukocytosis (.10,000/mm [3]) or fever (.38.08C). Ex-
Immunohistochemical studyclusion criteria were antibiotic use in the previous seven
days, known hypersensitivity to any b-lactam antibiotics, Immunohistochemical studies were performed on
cryostat tissue sections (4 mm). After fixation in acetonea poor clinical condition, renal insufficiency (estimated
creatinine clearance ,30 mL/min), pregnancy or breast for 15 minutes at room temperature, slides were washed,
preincubated first in 10% normal goat serum for 15 min-feeding, use of systemic corticosteroids or other immuno-
suppressive agents in the past three months, a history of utes, and then incubated for 16 hours at 48C with an
anti-human mouse IgG1 monoclonal anti-uPAR (CD87)seizures, use of any investigational drug within 30 days,
or any clinically significant medical condition that would R-phycoerythrin (PE)-conjugated antibody (Pharmin-
gen, San Diego, CA, USA). The endogenous peroxidasepose a risk to the patient should he/she participate. Pa-
tients received either a single dose of 1000 mg intrave- activity was then blocked using 0.1% NaN3 and 0.3%
H2O2 in phosphate-buffered saline (PBS) for 15 minutesnous ceftazidime or a single dose of 500 mg intravenous
imipemem, followed after eight hours by an antibiotic at room temperature. Sections were washed and incu-
bated with polymerized horseradish peroxidase (HRP)-chosen by the clinician. Urine and heparinized blood
were collected before the start of treatment (0 hour) and conjugated goat anti-mouse IgG antibody (Powervisione;
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Immunovision Techonology, Daly City, CA, USA). En- as well as between the uPAR concentration and the
APACHE II score were assessed by calculating thezyme activity of HRP was finally detected using 3-amino-
9-ethyl-carbazole and counterstained with hematoxylin. Spearman correlation. A probability of less than 0.05
was considered significant.
Cell culture
HK-2 cells, from the HPV 16-immortalized renal prox-
RESULTS
imal tubular epithelial cell line obtained from normal
Clinical and microbiology dataadult human kidney, were purchased from ATCC (Rock-
ville, MD, USA). Cells were grown to subconfluence in The duration of symptoms before the first urine and
plasma samples were taken was 2.9 6 0.3 (mean 6 SEM)conditioned medium consisting of a 1:1 ratio of Dulbec-
co’s modified Eagle’s medium (DMEM; ICN, Costa days. E. coli was cultured form the urine of all except
one patient. Ten patients had positive blood cultures,Mesa, CA, USA) and Ham’s F12 (DMEM/F12) medium
(Life Technologies, Paisley, UK) supplemented with 5% and all but one (Proteus mirabilis) were E. coli. The
median APACHE II score on admission was six (rangeheat-inactivated fetal calf serum (FCS; Life Technolo-
gies), 100 U/mL penicillin, 100 mg/mL streptomycin, 2 0 to 17). All patients fully recovered after treatment.
mmol/L L-glutamine, 5 mg/mL insulin, 5 mg/mL trans-
uPAR secretion in plasma and in urineferrin, 5 ng/mL sodium selenite, 20 ng/mL tri-iodothyro-
during urosepsisnine, 5 ng/mL hydrocortisone, 5 ng/mL PGE1, and 5
ng/mL epidermal growth factor, all obtained from Sigma The urokinase receptor uPAR was detectable at low
levels in plasma (1.9 6 0.4 ng/mL) and in urine (558 6(St. Louis, MO, USA). For passage, confluent cells were
harvested by trypsinization with 0.25% (wt/vol) trypsin- 66 ng/mmol creatinine) of healthy subjects. As shown in
Figure 1, both plasma and urine levels of uPAR were0.03% (wt/vol) ethylenediaminetetraacetic acid (EDTA)
in PBS and plated again in conditioned DMEM/F12. higher in patients with urosepsis on admission (plasma,
21.1 6 2.5 ng/mL, and urine, 18427 6 5958 ng/mmolFor activation, cells were grown to confluency and were
growth arrested in serum-free unconditioned medium creatinine) than in healthy controls (both P # 0.001). The
patients with positive blood cultures had a significantlyfor 24 hours, and all experiments were subsequently per-
formed in unconditioned medium supplemented with higher concentration of uPAR in plasma but not in urine
than patients with negative blood cultures (time of ad-0.5% FCS. Cells at a concentration of 1 3 105 cells/mL
were stimulated in 24-well plates with recombinant TNF-a mission, 32.8 6 4.6 vs. 16.3 6 1.9 ng/mL, P 5 0.006;
8 hours after admission, 35.6 6 7.2 vs. 15.0 6 2.2, P 5(10 ng/mL) or recombinant IL-1b (10 ng/mL; Strath-
mann Biotech, GmbH, Hannover, Germany). Superna- 0.002). However, no significant correlation could be found
between the individual APACHE II score and the levelstants were harvested after 24, 48, and 72 hours of culture
and were tested by enzyme-linked immunosorbent assay of uPAR in plasma and urine. The type of antibiotic
regimen did not significantly influence uPAR levels in(ELISA) for uPAR production.
urine or plasma (data not shown); therefore, both groups
ELISA were pooled for further analysis. During the follow-up
of eight hours, only urine levels of uPAR decreased (butUrokinase plasminogen activator receptor concentra-
tions were measured by ELISA according to the recom- not statistically significantly) eight hours after the initia-
tion of antibiotic treatment. At the time of admissionmendations of the manufacturer using purified mono-
clonal mouse antihuman uPAR (4 mg/mL; R&D Systems, and four hours after, a significant correlation between
uPAR concentrations in plasma and urine was foundAbingdon, UK) as coating antibody, biotinylated goat
anti-human uPAR (100 ng/mL; R&D Systems) as detect- (0 hour, r 5 0.411, P 5 0.041; 4 hours, r 5 0.469, P 5
0.012).ing antibody, and recombinant human uPAR (R&D Sys-
tems) as the standard. The detection limit of the assay
uPAR secretion during experimental endotoxemiawas 0.2 ng/mL. Urine concentrations are expressed as
ng/mmol creatinine to correct for dilution. To establish the role of the systemic inflammatory
reaction in the up-regulation of uPAR in the circulation
Statistical analysis and in the urinary tract, plasma and urine levels of uPAR
were measured at different time points after LPS injec-Data are given as mean 6 SEM when appropriate.
Comparisons of uPAR concentrations were done by tion in healthy humans. As shown in Figure 2A, LPS
induced a significant increase in plasma uPAR concen-Mann-Whitney U test except for the analysis of the evo-
lution of uPAR concentration in time during urosepsis tration, with a peak plasma level three hours after chal-
lenge (5.2 6 0.7 ng/mL, P # 0.001) to return to normaland experimental endotoxemia where the one-way anal-
ysis of variance (ANOVA) was applied. Correlations values after 12 hours (2.2 6 0.2 ng/mL). Urine concentra-
tions of uPAR increased within three hours after LPSbetween the uPAR concentration in urine and plasma
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Fig. 1. Plasma (A) and urine (B) levels of urokinase plasminogen acti-
vator receptor (uPAR) in healthy subjects (h) and in patients with
urosepsis (j). Samples from patients with urosepsis were collected on
admission (t 5 0) and at two, four, and eight hours after initiation of
antibiotic therapy. Results are expressed as mean 6 SEM. Patients with
urosepsis (N 5 30) had higher plasma and urine levels than controls
Fig. 2. Plasma and urine concentrations of uPAR during experimental(N 5 20) throughout the follow-up (both P , 0.001 at all time points).
endotoxemia. Plasma (A) and urine (B) concentrations of uPAR are
expressed as mean 6 SEM. Plasma concentrations of uPAR were mea-
sured prior to endotoxin injection (t 5 0) and during a follow up of 12
hours in seven healthy volunteers. Urine concentrations were measured
exposure (Fig. 2B). No leukocytes were found in urine prior to endotoxin injection (t , 0) and in urine collected between zero
and three hours after endotoxin administration (t 5 0 to 3) and betweenfrom any of the subjects injected with LPS at any time
three and six hours after endotoxin administration (t 5 3 to 6). Thepoint. There was no significant correlation between the asterisks indicate significant difference from the levels at t 5 0 (P ,
plasma and urine concentration of uPAR. 0.005).
Renal production of uPAR during urosepsis and
experimental endotoxemia
1, the ratio between the individual urine and plasmaHaving established that during urosepsis and experi-
levels of uPAR was significantly higher at all time pointsmental endotoxemia the secretion of uPAR both in
during urosepsis compared with normal subjects. Theplasma and in urine is significantly up-regulated, we
urine/plasma ratio during experimental endotoxemiasought to determine whether the kidney could be a major
source of uPAR in both situations. As shown in Table was also elevated, although the difference was not statis-
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Table 1. Urine/plasma ratio of urokinase plasminogen activator
receptor (uPAR) levels during urosepsis and
experimental endotoxemia
Groups Urine/plasma ratio of uPAR
Healthy subjects 433654
Urosepsis
t 5 0 9726187a
t 5 2 11476281a
t 5 4 9896152a
t 5 8 10086187a
LPS volunteers
t 5 0 6096401
t 5 3 10146353
t 5 6 13946387
Data are mean 6 SEM of the individual ratio of urine and plasma concentra-
tion of uPAR in healthy subjects (N 5 20), patients with urosepsis (N 5 30)
before initiation of antibiotic therapy (t 5 0), and 2, 4 and 8 hours after, and
healthy volunteers (N 5 7) prior to endotoxin injection (t 5 0), and 3 and 6
hours after the challenge.
a P # 0.02 compared with healthy subjects
tically significant. This high urine/plasma ratio suggests
the participation of the kidney in the production of
uPAR in the urine in both conditions. In order to confirm
these findings, renal tissues obtained from patients suf-
fering from chronic pyelonephritis were stained for
uPAR by immunohistochemistry. As shown in Figure
3A, damaged tubuli were clearly positive for uPAR. In
contrast, normal renal tissue did not show any positive
staining (Fig. 3B).
Regulation of the production of uPAR by renal
Fig. 3. Immunostaining for uPAR on renal tissue. Renal tissue ob-tubular epithelial cells in vitro
tained from patients with chronic pyelonephritis (A) and from normal
part of kidneys removed by nephrectomy for renal cell carcinoma (B)Having shown that uPAR is expressed on tubular epi-
were stained for uPAR. Damaged tubuli were clearly positive for uPARthelial cells during pyelonephritis and is secreted in large in chronic pyelonephritis (A), while normal renal tissue did not show
amounts in the urine during urosepsis and experimental any positive staining (B; original magnification 370).
endotoxemia, we studied the secretion of uPAR by renal
tubular epithelial cells in vitro. As shown in Table 2,
unstimulated proximal tubular epithelial cells produce
urine of LPS-exposed volunteers and of patients withsmall amounts of uPAR in vitro. After stimulation with
urosepsis. Since different cell types are able to expressIL-1b or TNF-a, the secretion of uPAR was significantly
uPAR, the cellular source of soluble uPAR in theseincreased.
patients and subjects exposed to LPS is probably multi-
ple. As far as the systemic production is concerned,
DISCUSSION monocytes and granulocytes are likely candidates since
the stimulation of human whole blood with endotoxinThis study demonstrates the following: (1) soluble
up-regulated the expression of uPAR on the surface ofuPAR is elevated in plasma and urine during urosepsis
monocytes [28] and granulocytes (unpublished data).and experimental endotoxemia; (2) uPAR is expressed
The lack of correlation between urine and plasma lev-by tubular epithelial cells during pyelonephritis; and (3)
els of uPAR suggests that both systemic and renal pro-tubular epithelial cells stimulated with IL-1b or TNF-a
duction of uPAR take place during experimental endo-produce large amounts of uPAR in vitro. Elevated solu-
toxemia. The large amounts of soluble uPAR found inble uPAR concentrations have been reported in the cir-
the urine during urosepsis and experimental endotoxe-culation of healthy volunteers after LPS administration
[28], in patients with sepsis syndrome [29], with paroxys- mia may reflect either its clearance from blood, its local
production, or both. The relative high urine concentra-mal nocturnal hemoglobinuria [30], and with advanced
malignancies [31, 32]. In the present study, we found tion of uPAR, the elevated urine/plasma ratio of uPAR
during urosepsis and experimental endotoxemia, and thehigh levels of soluble uPAR in both the plasma and the
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Table 2. uPAR secretion by tubular epithelial cells in vitro face of other cell types has been described. Briefly,
IFN-g, TNF-a, LPS, and urokinase collectively up-regu-uPAR (ng/mL) secretion after stimulation witha
late the expression of uPAR on the surface of humanStimulation during 0 IL-1b 10 ng/mL TNF-a 10 ng/mL
monocytes, while granulocyte/macrophage-colony stim-
24 hours 0.260.1 0.860.3a 0.660.2a
ulating factor (GM-CSF) has no effect [7, 28]. Phorbol48 hours 0.960.2 1.960.5a 1.460.4a
72 hours 1.060.3 2.360.6a 1.660.4 myrisate acetate (PMA), phytohemagglutinin (PHA),
uPAR (ng/mL) secretion in supernatants of tubular epithelial cells unstimu- concanavalin A (Con A), IL-2, IL-4, and IL-7 induce
lated (0) and stimulated with IL-1b or TNF-a for 24, 48 and 72 hours. These the expression of uPAR at the surface of T cells. Thisresults are expressed as mean 6 SEM of 4 independent experiments.
a P , 0.05 compared to unstimulated cells induction is inhibited by transforming growth factor-b
(TGF-b) [10]. As far as endothelial cells are concerned,
PMA and basic fibroblast growth factor (FGF), but not
TGF-b, can increase the production of uPAR [11, 44].expression of uPAR on tubular epithelial cells in pyelo-
The exact function of soluble uPAR during infectionnephritis show that a local production of uPAR occurs
remains to be elucidated. Soluble uPAR may facilitateduring renal inflammation. Recent evidence has high-
the b2 integrin-dependent adhesion of cells and/or vitro-lighted that renal tubules are not only targets, but are
nectin-mediated binding of uPA, especially when cellsalso active participants in immune reactions. These cells
lack membrane-bound uPAR [18, 20, 21]. Soluble uPARexert crucial immunologic functions such as processing
has been found to inhibit uPA binding to uPAR express-and presenting of foreign proteins [33] and secretion
ing cells, conceivably by competing with cell-associatedof proinflammatory cytokines such as IL-6 and TNF-a
uPAR for the binding of free uPA. The involvement of[34, 35], of chemokines [36–40] and of complement com-
uPAR in leukocyte invasion through extracellular matri-ponents (C3, C4, factor B) [41]. Different stimuli are
ces is suggested by its expression on a variety of migra-able to activate tubular epithelial cells in vitro, among
tory cells and its polarization at the leading edge ofwhich are IL-1, IL-2, interferon-g (IFN-g), and the liga-
migrating monocytes [45–47]. In vitro studies have furthertion of CD40 [42]. In the present study, we show a clear
indicated that uPAR is crucial for chemotaxis of neutro-expression of uPAR on the surface of damaged tubular
phils and monocytes, suggesting that uPAR plays anepithelial cells during pyelonephritis and a sustained se-
important role in the orchestration of inflammatory reac-cretion of uPAR by tubular epithelial cells in vitro after
tions [9, 16, 47]. Little is known about uPAR regulationstimulation with IL-1b or TNF-a. To the best of our
and function in vivo, but recently, it has been reportedknowledge, there is only one study describing the distri-
that uPAR-deficient mice have a defective b2-integrin–bution of uPAR in renal tissue in which uPAR expres-
dependent migration of neutrophils into the peritonealsion was found in all segments of the tubular epithelium
cavity after injection with thioglycollate [48] and an im-in normal renal tissue by immunohistochemistry [13].
paired neutrophil recruitment in response to pulmonaryProbably because of the use of other monoclonal anti-
Pseudomonas aeruginosa infection [17]. Besides the sys-bodies, significant staining for uPAR was observed in
temic and local role of uPAR in fighting infection, theonly damaged tubuli during pyelonephritis. Along the
local expression and secretion of this receptor duringsame line, no expression for uPAR could be detected
renal inflammation may also fulfill an essential functionby FACS analysis on resting tubular epithelial cells (data
in the maintenance of patency of the tubuli. Indeed, thenot shown), but mRNA for uPAR was clearly present
binding of the zymogen pro-uPA to its receptor initiatesin unstimulated tubular epithelial cells by polymerase
an enzymatic cascade and induces the formation of plas-chain reaction analysis (data not shown). Altogether,
min, a trypsin-like protease. The presence of plasmino-these data suggest that tubular epithelial cells probably
gen activators is believed to be essential for the preven-express a low level of uPAR under normal conditions
tion of fibrin clot formation in both the kidney and theand that this expression is up-regulated by inflammation.
urine [13]. Tubular damage and tubulointerstitial fibrosisAccordingly, unstimulated tubular epithelial cells secrete
are frequent sequelae of pyelonephritis and contributesmall amounts of uPAR in vitro, and this secretion is
to the development chronic renal failure. Since the pro-increased by fourfold after stimulation with IL-1b and
teolytic activity of plasmin also plays a role in woundby threefold after stimulation with TNF-a. Both cyto-
repair and matrix degradation [49], plasmin probablykines are known as powerful proinflammatory stimuli
contributes to renal tissue remodeling by activation offor tubular epithelial cells [42, 43]. These in vitro data
latent metalloproteinases, which degrade extracellularsuggest that the systemic release of inflammatory media-
matrix proteins in the kidney [50–52]. Future studies intors (among which are IL-1 and TNF-a induced by LPS
animal models are needed to determine the exact func-in vivo) can trigger the production of uPAR by tubular
tion of uPAR in the clearance of infection, in the preser-epithelial cells. This mechanism can explain the high
vation of renal function, and in the prevention of renalurine/plasma ratio of uPAR during experimental endo-
toxemia. The regulation of uPAR expression on the sur- scarring during pyelonephritis and urosepsis.
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